The Specimen Core will provide SPORE investigators with well-characterized biologic specimens, including tissues, blood, and tissue derivatives, that are essential for achieving the aims ofthe projects. The Specimen Core has a large repository of paraffin blocks, frozen samples, plasma, serum, and bone marrow that spans the entire spectrum of prostate cancer. The repository includes primary tumors and metastases from therapy-resistant tumors and tumors derived from radical prostatectomy specimens from patients given novel preoperative therapies as part of studies conducted at The University of Texas M. D. Anderson Cancer Center and other, multi-institutional efforts. This material, supplemented in select cases with matching biopsy specimens, plasma, serum, and bone marrow aspirates collected before therapy, will provide SPORE investigators with optimal tissue samples with which to address the proposed basic and translational research tissue requirements of the projects. We have also established biologic models (cell lines and xenografts) relevant to the projects. Tissue requests and approval by the Tissue Acquisition and Distribution Committee will be handled electronically. Tissue derivatives, including tissue microarrays, cRNA, and DNA, will optimize the use of limited samples and enhance collaboration among investigators at M. D. Anderson and other institutions. Structured information derived from standardized, high-throughput assays of differential gene expression, both of protein (immunohistochemistry) and RNA (oligonucleotide arrays and multiplexed PCR), will be available to individual SPORE investigators to facilitate modular and gene network analysis in specific clinical contexts. A unique feature of the Specimen Core will be the ability to link comprehensive clinical and pathologic information to the morphologic and molecular characterization of selected pathways. This linkage will be accomplished, in cooperation with the Biostatistics and Bioinformatics Core, by using a Web-based portal. By using this Web-based system to access and query SPORE data, we will pool laboratory resources, facilitate the translational research proposed in the projects, and accelerate successful achievement of the proposed aims.
^ The Specimen Core will collect, store and distribute tissue and blood samples from patients with prostate cancer. The Core will also create and maintain cell lines and xenografts from samples of prostate cancer tissues. These materials are essential to conduct the projects of this SPORE proposal. The Core will provide technical support and pathologic expertise to the investigators and will link the clinical and pathologic information to the results obtained from the various experiments.
|Zhang, Tao; Tseng, Chieh; Zhang, Yan et al. (2016) CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674|
|Sun, Sheng; Sun, Le; Zhou, Xi et al. (2016) Phosphorylation-Dependent Activation of the ESCRT Function of ALIX in Cytokinetic Abscission and Retroviral Budding. Dev Cell 36:331-43|
|Hosoya, Hitomi; Dobroff, Andrey S; Driessen, Wouter H P et al. (2016) Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A 113:1877-82|
|Maity, Sankar N; Titus, Mark A; Gyftaki, Revekka et al. (2016) Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep 6:35354|
|Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207|
|Han, Ying; Rand, Kristin A; Hazelett, Dennis J et al. (2016) Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. J Natl Cancer Inst 108:|
|Varkaris, Andreas; Corn, Paul G; Parikh, Nila U et al. (2016) Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22:107-21|
|Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D inÂ vitro model of patient-derived prostate cancer xenograft for controlled interrogation of inÂ vivo tumor-stromal interactions. Biomaterials 77:164-72|
|Weiderhold, Kimberly N; Fadri-Moskwik, Maria; Pan, Jing et al. (2016) Dynamic Phosphorylation of NudC by Aurora B in Cytokinesis. PLoS One 11:e0153455|
|Qiao, Yuanyuan; Feng, Felix Y; Wang, Yugang et al. (2016) Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia 18:1-9|
Showing the most recent 10 out of 167 publications